FDA Approved: ROCKLATAN — Supplemental Application (Alcon Laboratories, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ROCKLATAN (netarsudil and latanoprost ophthalmic solution) submitted by Alcon Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension

Drugs mentioned

• ROCKLATAN (Netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%)

Snippet

SUPPL AP for ROCKLATAN (NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005%)